%0 Journal Article
%A Afshar-Oromieh, Ali
%A Holland-Letz, Tim
%A Giesel, Frederik L
%A Kratochwil, Clemens
%A Mier, Walter
%A Haufe, Sabine
%A Debus, Nils
%A Eder, Matthias
%A Eisenhut, Michael
%A Schäfer, Martin
%A Neels, Oliver
%A Hohenfellner, Markus
%A Kopka, Klaus
%A Kauczor, Hans-Ulrich
%A Debus, Jürgen
%A Haberkorn, Uwe
%T Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.
%J European journal of nuclear medicine and molecular imaging
%V 44
%N 8
%@ 1619-7089
%C Heidelberg [u.a.]
%I Springer-Verl.
%M DKFZ-2017-01306
%P 1258 - 1268
%D 2017
%X Since the clinical introduction of (68)Ga-PSMA-11 PET/CT, this imaging method has rapidly spread and is now regarded as a significant step forward in the diagnosis of recurrent prostate cancer (PCa). The aim of this study was to analyse the influence of several variables with possible influence on PSMA ligand uptake in a large cohort.We performed a retrospective analysis of 1007 consecutive patients who were scanned with (68)Ga-PSMA-11 PET/CT (1 h after injection) from January 2014 to January 2017 to detect recurrent disease. Patients with untreated primary PCa or patients referred for PSMA radioligand therapy were excluded. The possible effects of different variables including PSA level and PSA doubling time (PSADT), PSA velocity (PSAVel), Gleason score (GSC, including separate analysis of GSC 7a and 7b), ongoing androgen deprivation therapy (ADT), patient age and amount of injected activity were evaluated.In 79.5
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:28497198
%R 10.1007/s00259-017-3711-7
%U https://inrepo02.dkfz.de/record/124429